Compare OLP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | OMER |
|---|---|---|
| Founded | 1982 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.9M | 844.6M |
| IPO Year | 1995 | 2008 |
| Metric | OLP | OMER |
|---|---|---|
| Price | $23.89 | $18.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $26.75 | ★ $32.50 |
| AVG Volume (30 Days) | 67.6K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ 1.00 | 0.77 |
| Revenue | ★ $82,740,000.00 | $29,868,000.00 |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $3.71 | $233.22 |
| P/E Ratio | ★ $23.86 | $24.35 |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $3.94 |
| 52 Week High | $25.88 | $19.65 |
| Indicator | OLP | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 70.49 |
| Support Level | $23.31 | $9.12 |
| Resistance Level | $25.74 | $19.65 |
| Average True Range (ATR) | 0.44 | 0.98 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 9.37 | 73.38 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.